.Nature Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for inclusion of individuals along with MASLD and measurement of liver outcomes in cardio-- kidney-- metabolic trials, when records suggest mechanistically conceivable perks as well as scientific safety and security-- and summarizes factors to consider for test layout and also regulatory approval.